Previous close | 0.0900 |
Open | 0.0800 |
Bid | 0.0200 |
Ask | 0.2800 |
Strike | 220.00 |
Expiry date | 2024-10-18 |
Day's range | 0.0800 - 0.0800 |
Contract range | N/A |
Volume | |
Open interest | 14 |
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
Despite becoming one a household name during the pandemic, Moderna stock has mostly fallen over the past three years amid slow sales.
The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.